Vascular endothelial growth factor (VEGF) has a central role in breast cancer development and progression, but the mechanisms that control its expression are poorly understood. Breast cancer tissue microarrays revealed an inverse correlation between the Forkhead transcription factor Forkhead box class O (FOXO)3a and VEGF expression. Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated by FOXO3a. Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression. Transient transfection and inducible expression experiments showed that FOXO3a represses the proximal VEGF promoter, whereas another Forkhead member, FOXM1, induces VEGF expression. Chromatin immunoprecipitation and oligonucleotide pull-down assays showed that both FOXO3a and FOXM1 bind a consensus Forkhead response element (FHRE) in the VEGF promoter. Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF. These results show that FOXO3a-dependent repression of target genes in breast cancer cells, such as VEGF, involves competitive displacement of DNA-bound FOXM1 and active recruitment of transcriptional repressor complexes.
Introduction
The vascular endothelial growth factor (VEGF) family of growth factors, consisting of six members, VEGF-A (commonly called VEGF), VEGF-B, -C, -D, -E and the placental growth factor, has a crucial role in the tissue development and maintenance through regulating the processes of vasculogenesis, angiogenesis and lymphangiogenesis (Lohela et al., 2009) . These VEGF ligands bind to three distinct primary receptors and two coreceptors to trigger downstream intracellular signalling. Of the primary receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) are associated predominantly with angiogenesis, and VEGFR-3 (Flt-4) to lymphangiogenesis. VEGFR-2 is expressed ubiquitously on almost all endothelial cell types, whereas the expression of VEGFR-1 and -3 is restricted to particular vascular supporting tissues. The neuropilin-1 and -2 receptors are co-receptors that can enhance the binding affinity of the various VEGF ligands to the primary receptors. Upon ligand binding, the VEGF receptors activate downstream signalling cascades, including the phosphatidylinositol 3-kinase (PI3K)-Akt (protein kinase B), the p38-mitogen-activated protein kinase and the Raf pathways, which in turn control the endothelial cell survival, proliferation and migration (Lentzsch et al., 2004; Pytel et al., 2009) . VEGF and its receptors are frequently overexpressed in human tumours, especially in breast, non-small cell lung, colorectal and prostate cancers (Ferrer et al., 1998; Schneider and Sledge, 2007; Yamaguchi et al., 2007; Heist et al., 2008; Jain et al., 2009) . VEGF mediates angiogenesis, a process that has a central role in the growth, progression and metastasis of solid tumours (Makrilia et al., 2009; Kitadai, 2010) . In consequence, VEGF and associated signalling pathways have been the targets for many novel anti-cancer targeted therapeutics (Margolin, 2002) . For instance, bevacizumab, an anti-VEGF antibody, has been shown to enhance response rates and prolonged progressionfree survival in metastatic breast cancer. Similarly, inhibition of the VEGF signalling by receptor tyrosine kinase inhibitors, including sunitinib, decrease proliferation of numerous cancer cells in vitro (Ikezoe et al., 2006a, b) . Besides being a therapeutic target, VEGF is also a rational prognostic marker in many cancers (Margolin, 2002) . For example, VEGF expression in gastric cancer has been shown to be an independent negative prognostic marker (Ferrer et al., 1998; Schneider and Sledge, 2007; Yamaguchi et al., 2007; Heist et al., 2008; Jain et al., 2009) .
The PI3K-Akt cell proliferation and survival signalling pathway has a key role in tumourigenesis of many cancers as well as in the development of anti-cancer chemotherapy resistance. The Forkhead box class O (FOXO) transcription factors are crucial downstream effectors of the PI3K-Akt signalling pathway and are implicated in a wide variety of cellular functions including cell proliferation, apoptosis, differentiation and resistance to oxidative stress and DNA damage (Lam et al., 2006; Reedquist et al., 2006; Huang and Tindall, 2007; Myatt and Lam, 2007; Arden, 2008; Burgering, 2008; Calnan and Brunet, 2008; Fu and Tindall, 2008; Gomes et al., 2008; Ho et al., 2008; Maiese et al., 2008) . As such, deregulation of FOXO proteins is associated with tumourigenesis and cancer progression. In addition, emerging evidence has also showed that FOXO proteins, in particular the FOXO3a, has a central role in mediating the cytostatic and cytotoxic effects of chemotherapy (Sunters et al., 2003 (Sunters et al., , 2006 Fernandez de Mattos et al., 2004 Myatt and Lam, 2007; Gomes et al., 2008; Ho et al., 2008; Hui et al., 2008a, b; McGovern et al., 2009) . The mammalian FOXO family of transcription factors comprises of four members, FOXO1, FOXO3a, FOXO4 and FOXO6, and they are direct substrates of Akt (Myatt and Lam, 2007) . FOXO proteins interact with a core consensus DNA sequence 5 0 -GTAAA(C/T)A-3 0 to modulate target gene expression. Phosphorylation of FOXOs by Akt results in their nuclear exclusion and inactivation.
Lapatinib (GW572016) is a small molecule dual tyrosine kinase inhibitor for HER2 and epidermal growth factor receptor (EGFR) that functions through competitive inhibition of ATP binding to the receptor tyrosine kinase domain (Wakeling, 2002; Ciardiello, 2005; Nelson and Dolder, 2006) . Lapatinib has been shown to cause growth delay and cell death in breast cancer cell lines and human tumour xenografts expressing high levels of EGFR and/or HER2. Recent phase II/III clinical studies also showed that lapatinib was well tolerated and provided anti-tumour activity in patients with breast as well as with other types of cancer when used as a monotherapy or in combination with other anti-cancer treatments (Ciardiello, 2005; Montemurro et al., 2007) . Most recent studies showed lapatinib displays antiangiogenic effect in a lung cancer model (Diaz et al., 2010) and that combination treatment of lapatinib with paclitaxel, but not lapatinib alone, effectively inhibits angiogenesis in head and neck squamous cell carcinoma cells (Kondo et al., 2010) . However, although enhanced HER2/EGFR expression may have been shown to function primarily through two pathways the ERK1/2 mitogen-activated protein kinase and PI3K-Akt signalling cascades (Yarden and Sliwkowski, 2001; Montemurro et al., 2007; Zhang et al., 2007) , a complete understanding of the mechanism by which HER2/EGFR promotes tumourigenesis remains lacking. Latest work shows that FOXO3a has an essential role in mediating the cytostatic and cytotoxic function of lapatinib as well as the EGFR-specific tyrosine kinase inhibitor gefitinib (Hegde et al., 2007; Krol et al., 2007; McGovern et al., 2009) .
A recent cDNA microarray study revealed that FOXO3a can potentially repress VEGF expression in a colon carcinoma cell line (Delpuech et al., 2007) . In this study, we validated this notion in breast cancer patient samples and then went on to investigate the molecular mechanism by which FOXO represses VEGF expression.
Results

Inverse correlation between FOXO3a and VEGF expression in breast cancer
The expression patterns of FOXO3a, FOXM1 and VEGF were examined in a panel of breast cancer samples by immunohistochemistry. Representative patterns of staining are shown in Figure 1a . FOXO3a immunoreactivity was predominantly cytoplasmic in most tumour samples and correlated positively with VEGF (P ¼ o0.001, w 2 -test) and FOXM1 (P ¼ 0.011, w 2 -test) staining irrespective of histological type, suggesting that the activated nuclear FOXO3a inhibits FOXM1 and VEGF expression in vivo in most breast cancer samples ( Figure 1b and Supplementary Figure S1 -5). Notably, there was also an inverse association between nuclear FOXO3a and VEGF expression but it was not statistically significant. Moreover, FOXM1 expression also significantly correlated with the expression of VEGF (P ¼ 0.015, w 2 -test), suggesting FOXM1 promotes VEGF expression in breast cancer cells (Figure 1b and Supplementary Figure S6 ).
FOXO3a activation correlates with downregulation of FOXM1 and VEGF expression FOXM1 has recently been suggested to regulate VEGF expression (Zhang et al., 2008) and to be regulated by FOXO3a . To determine whether FOXO3a and FOXM1 also modulates VEGF transcription, we first monitored the expression of VEGF, FOXM1 and FOXO3a upon lapatinib treatment of responsive and resistant breast cancer cell lines. Western blot analysis showed that lapatinib treatment of sensitive BT474 and SKBR3 cells caused a decline in phosphorylation but an increase in nuclear FOXO3a levels, indicating activation of this transcription factor (Figure 2a ). FOXO3a activation upon lapatinib treatment was accompanied by a decrease in VEGF and FOXM1 levels. The result also showed that another growth factor FGF7 was not downregulated by lapatinib, suggesting that the repression of VEGF expression by lapatinib and FOXO3a is specific. Notably, all factors were downregulated in BT474 cells after 48 h, probably reflecting global protein degradation and cell death. In contrast, there were no appreciable changes in P-FOXO3a, nuclear FOXO3a, FOXM1 or VEGF levels upon treatment of lapatinibresistant MDA-MB-231 breast cancer cells.
To confirm that lapatinib represses VEGF expression, secreted levels of VEGF were determined by enzymelinked immunosorbent assay in the three cell lines (Figure 2b ). Although secreted VEGF levels remained unchanged upon lapatinib treatment of MDA-MB-231 cells, the levels declined markedly after 24 h treatment of Histological sections of all cases were reviewed by the pathologist, the representative paraffin tumour blocks chosen as donor block for each case and the selected areas marked for construction of tissue microarray blocks. Tissue sections were deparaffinised, rehydrated and stained with a previously described primary polyclonal FOXO3a-specific antibody (Nordigarden et al., 2009 , Rosivatz et al., 2006 ) (diluted at 1:1400), the VEGF antibody (dilution 1:250) and FOXM1 (C-20, dilution 1:450, Santa Cruz Biotechnology, Santa Cruz, CA, USA). A total of 116 could be assessed and scored for FOXO3a, FOXM1 and VEGF expression using a scanscope (Aperio Technologies, Inc., Vista, CA, USA) connected to a personal computer as described in Supplementary Figure S1 . The expression pattern and subcellular localisation were correlated with histological type, histological grade, clinical stage, oestrogen and progestrogen receptor status, HER2 oncoprotein overexpression, lymph node metastasis and survival time (Supplementary Figures S2 and S3) . Tumour tissue samples obtained from breast cancer patients that had been formalin fixed and paraffin embedded were immunohistochemically stained with FOXO3a, FOXM1 and VEGF antibodies using the streptavidin-biotin-peroxidase technique. Scoring was performed as described in Supplementary Figure S1 . (a) Three representative tumour cases showing corresponding FOXO3a FOXM1 and VEGF staining patterns (magnification, Â 100; insets Â 400). The three cases 1, 2 and 3 represent low, medium and high FOXO3a cytoplasmic staining. Cases 1 and 2 also show nuclear FOXO3a staining and low FOXM1 and VEGF staining, whereas case 3 shows predominantly strong cytoplasmic FOXO3a staining, and strong FOXO3a and VEGF staining. (b) Correlation analysis of FOXO3a, FOXM1 and VEGF staining in 116 breast carcinoma cases. The correlation between predominant nuclear/cytoplasmic FOXO3a expression with FOXM1 and VEGF expression and FOXM1 with VEGF expression was studied using w 2 -tests and was considered significant at *Pp0.05 and very significant at **Pp0.01. Figure S7) . The results showed that the concentrations of the irrelevant control growth factor FGF7 did not alter significantly after lapatinib treatment in BT474, SKBR3 and MDA-MB-231 cells, suggesting that the repression of VEGF by FOXO3a and lapatinib is specific. We then tested if lapatinib regulated VEGF, FOXM1 or FOXO3a expression at the transcriptional level. Realtime-quantitative(q)PCR analysis confirmed that lapatinib inhibited VEGF and FOXM1 mRNA expression in the sensitive SKBR3 but not the resistant MDA-MB-231 cells (Figure 2c ). Notably, FOXO3a transcript levels were also upregulated in SKBR3 cells. Together these results demonstrate that lapatinib treatment of sensitive breast cancer cells induces and activates FOXO3a but inhibits FOXM1 and VEGF expression.
FOXO3a represses VEGF and FOXM1 expression
To study the mechanism underlying the reciprocal relationship between FOXO3a activation and VEGF and FOXM1 inhibition, we used an oestrogen receptor (b) VEGF concentrations in supernatants of the lapatinib-treated breast cancer cells were measured by a quantitative sandwich enzyme immunoassay according to the manufacturer's protocol (Quantikine enzyme-linked immunosorbent assay, R&D Systems, Abingdon, UK). The optical density was measured at 450 nm using a Sunrise-Tecan plate reader (TECAN Ltd., Reading, UK) and VEGF concentrations normalised using standard curves. (c) In parallel, VEGF mRNA levels of these lapatinib-treated breast cancer cells were also analysed by quantitative real-time (qRT)-PCR and normalised to L19 RNA expression. Total RNA (2 mg) isolated using the RNeasy Mini kit (Qiagen) was reverse transcribed using the Superscript III reverse transcriptase and random primers (Invitrogen, Paisley, UK), and the resulting first strand cDNA was used as template in the RT-PCR. All experiments were performed in triplicate. The following gene-specific primer pairs were designed using the ABI Primer Express software: FOXM1-sense: 5 0 -TGCAGCTAGGGATGTGAATCTTC-3 0 and FOXM1-antisense: 5 0 -GGAGCCCAGTCCATCAGAACT-3 0 ; ERa-sense: 5 0 -CAGATGGTCAGTGCCTTGTTGG-3 0 and ERa-antisense: 5 0 -CCAAGAGCAAGTTAGGAGCAAACAG-3 0 ; L19-sense 5 0 -GC GGAAGGGTACAGCCAAT-3 0 and L19-antisense 5 0 -GCAGCC GGCGCAAA-3 0 . Specificity of each primer was determined using NCBI BLAST module. RT-PCR was performed with ABI PRISM 7700 Sequence Detection System using SYBR Green Mastermix (Applied Biosystems, Brackley, UK). The RT-qPCR results shown are representative of three independent experiments. FOXM1 mRNA levels of these cells were also analysed by RT-qPCR, and normalised with L19 RNA expression.
showed that the FOXO3a(A3) mutant inhibited FOXM1 and VEGF expression, at protein and mRNA levels, respectively (Figure 3c ). Conversely, transiently transfection of MCF-7 cells with a FOXO3a targeting small interfering RNA (siRNA) pool or non-targeting control siRNA increased VEGF and FOXM1 expression (Figure 3d ). To demonstrate further that FOXO3a has a role in the downregulation of FOXM1 and VEGF by lapatinib treatment, we transfected the BT474 breast carcinoma cells with either a FOXO3a-specific or a nonspecific control siRNA pool and studied the expression of VEGF and FOXM1 after lapatinib treatment (Figure 3e ). Western blot analysis showed that the FOXO3a-specific siRNA, but not control siRNA, effectively knocked down the expression of endogenous FOXO3a in the BT474 cells. As observed previously, Lapatinib treatment led to a decrease in P-HER2 in both control and FOXO3a siRNA cells. However, silencing of FOXO3a elevated the basal expression levels of FOXM1 and VEGF, and alleviated the downregulation of FOXM1 and VEGF by lapatinib. Notably, the expression levels of FOXM1 and VEGF did eventually decline at 48 h after lapatinib, which could be because of the functional compensation by other FOXO isoforms or the fact that FOXM1 and/or VEGF are also repressed by lapatinib through other transcription factors or at the post-transcriptional level. Together these data further confirmed that FOXO3a negatively regulates VEGF and FOXM1 expression, through a mechanism likely to involve transcriptional inhibition.
FOXO3a and FOXM1 modulate VEGF promoter activity
We postulated that FOXO3a could suppress VEGF transcription, either by modulating promoter activity or, indirectly, by inhibiting FOXM1 expression. To differentiate between these scenarios, a 1741-bp region of the putative VEGF promoter, representing positions À1926 to À186 relative to the predominant 5 0 -transcription start site was cloned upstream of a luciferase reporter (Figure 4a ). Co-transfection studies showed that expression of the FOXO3a(A3) mutant represses the activity from the putative VEGF promoter, whereas exogenous expression of FOXM1 transactivated the reporter construct in a dose-dependent manner (Figure 4b ). Sequence analysis identified two consensus Forkhead response elements (FHREs) in the proximal promoter region. Mutation of the distal (À319) but not the proximal (À178) FHRE abrogated the ability of FOXO3a(A3) and FOXM1 to inhibit and activate, respectively, this promoter-reporter construct. Thus, a 
FOXO3a and FOXM1 compete for binding to FHRE2
To provide more insight into the mechanism by which FOXO3a and FOXM1 regulates the VEGF promoter, we performed oligonucleotide pull-down assay with nuclear lysates from unstimulated MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells or cells treated with 4-OHT for 8 and 24 h. Western blot analysis of the pulled-down complexes showed that both FOXO3a and FOXM1 bind to the wild-type FHRE2 of VEGF, but not the mutated FHRE2 site (Figure 4c ). The binding of FOXO3a and FOXM1 to the FHRE2 could be competed off by excess amounts of the wild type but not mutated FHRE2 oligonucleotides, indicating that both transcription factors bind directly to this response element (Figure 4c) . The results also revealed that FOXM1 is constitutively bound to FHRE2 in untreated The FHRE pull-down experiment was then repeated in the BT474 cells following lapatinib treatment in the presence of molar excess of mutated FHRE oligonucleotides (Figure 4c) . Parallel western blot analysis of nuclear and cytoplasmic lysates showed that lapatinib induces nuclear accumulation of FOXO3a after 2-4 h, concomitant with the downregulation of VEGF expression but without discernible change in FOXM1 levels at these time-points (Figure 4d) . The pull-down results, however, indicated that the lapatinib-activated FOXO3a displaces FOXM1 from the FHRE2 of the VEGF promoter at these time-points. Thus, although prolonged activation of FOXO3a will downregulate FOXM1 levels, inhibition of VEGF expression is an early event and mediated, at least in part, by displacing FOXM1 and binding to FHRE2. Consistent with this, we have also obtained data from FHRE pull-down and chromatin immunoprecipitation (ChIP) assays, suggesting that FOXO3a can displace FOXM1 binding to the FHRE2 of the VEGF promoter (Supplementary Figure  S9) . Conversely, FOXM1 was unable to compete FOXO3a off the VEGF promoter. The finding that FOXO3a can displace FOXM1 from the VEGF FHRE2 and not vice versa is further supported by a recent structural study of the FOXM1 DNA-recognition FOXO3a is recruited to the proximal region of the VEGF promoter in vivo We next performed chromatin ChIP assays to determine the in vivo occupancy of the VEGF promoter in the BT474 cells in response to lapatinib treatment. The anti-FOXO3a antibody, but not the control antibody (immunoglobulin G), precipitated the proximal region, encompassing FHRE2, of the VEGF promoter in BT474 cells (Figure 4e ). The amount of precipitated DNA increased significantly following 2 h of lapatinib treatment, reflecting enhanced occupancy of FOXO3a to this region of the VEGF promoter in vivo, consistent with the DNA pull-down results. In contrast, the binding of FOXM1 decreased at 2 h following lapatinib treatment. Notably, the binding of both the FOXO3a and FOXM1 to the VEGF promoter decreased substantially by 4 h, probably suggesting decreased accessibility to the proximal region of the VEGF promoter. This observation pointed to the possibility that FOXO3a has a role in recruiting chromatin-remodelling enzymes, such as histone deacetylases (HDACs), to repress the VEGF transcription.
FOXO3a recruits HDAC2 to the VEGF promoter
To test the hypothesis that FOXO3a recruits HDACs to repress VEGF transcription, we first treated MCF-7 cells with the HDAC inhibitor trichostatin A and monitored VEGF expression. Real-time-qPCR and western blot analyses showed that trichostatin A strongly enhances VEGF mRNA and protein levels (Figure 5a ). Trichostatin A also triggered a marked induction in VEGF promoter activity, which was abolished upon mutation of the FHRE2, but not FHRE1, site. Conversely, overexpression of the dominantly active HDAC2 C262A/C274A mutant, but not the wild-type HDAC2, repressed VEGF promoter activity in a dose-dependent manner (Figure 5b ). This ability of HDAC2 to repress VEGF promoter activity was again dependent on a functional FHRE2. The inability of wild-type HDAC2 to repress VEGF promoter activity could be due to the high levels of endogenous HDAC2 in MCF-7 cells. ChIP assays further showed that trichostatin A induced a decrease in HDAC2 binding to the proximal VEGF promoter (Figure 5c ). Finally, HDAC2 knockdown using siRNA significantly upregulated VEGF expression, whereas silencing of HDAC1 silencing had little or no effect on VEGF expression. Combined, the data provide compelling evidence that HDAC2 mediates transcriptional inhibition of the VEGF promoter in breast cancer cells.
To examine if FOXO3a recruits HDAC2 to the VEGF promoter, we performed immunoprecipitation and ChIP experiments on BT474 cells treated with lapatinib. HDAC2 and FOXO3a co-immunoprecipitated and this interaction was enhanced upon lapatinib treatment, probably reflecting nuclear translocation of FOXO3a (Figure 6a ). ChIP assays showed increased recruitment of HDAC2 to the proximal VEGF promoter after 2 h of lapatinib treatment (Figure 6b ). Histone H3 and H4 acetylation are epigenetic marks associated with activated promoters (Davie and Candido, 1978; Bernstein et al., 2005) . HDAC2 recruitment coincided with a decrease in bound acetylated histones H3 and H4, indicating active chromatin remodelling and compaction of the proximal VEGF promoter. Further, siRNAmediated FOXO3a knockdown (Figures 6c and d 0 -transcription start site) was cloned into the XhoI and HindIII sites of the pGL3 basic vector (Promega). Putative Forkhead site mutagenesis was performed using a Stratagene QuikChange site-directed mutagenesis kit with the oligonucleotides: Site 1 (À178) (5 0 -ATCCCTCTTCTTTTTTCTTGGGCATTTTTTTTTAAAACTGTA TTGT-3 0 ), and Site 2 (À319) (5 0 -TTGCTCTACTTCCCCGGGTCACTGTGGATTTTGGGGGCCAGCAGA-3 0 ). (b) MCF-7 cells were transiently transfected with 20 ng of the wild-type, (VEGF pro-WT), mutant FHRE1 (VEGF pro-mut1) or mutant FHRE2 (VEGF pro-mut2) VEGF promoter/reporter and 0, 5, 10 or 20 ng of either the constitutively active FOXO3a(A3) or FOXM1(DN) expression vector. Cells were harvested 24 h after transfection and assayed for luciferase activity. All relative luciferase activity values are corrected for cotransfected Renilla activity. All data shown represent the averages of data from three independent experiments, and the error bars show the s.d.s. (c) MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 200 nmol/L 4-OHT for the indicated times. Nuclear extracts prepared were incubated with biotinylated wild type or mutant FHRE2 oligonucleotides in the presence or absence of 5 Â molar excess of non-biotinylated wild type or mutant FHRE2 oligonucleotides. Proteins binding to the biotinylated oligonucleotides were pulled-down using streptavidine agarose beads and analysed by western blot using specific antibodies as indicated. (d) The nuclear and cytoplasmic extracts prepared from BT474 cells treated with lapatinib for 0, 2 and 4 h were western blotted for proteins indicated (right panel). The nuclear extracts from the lapatinib-treated cells were also examined by pulldown assays using biotinylated wild type or mutant FHRE2 oligonucleotides as described above. (e) Chromatin immunoprecipitation analysis of the human VEGF promoter. MDA-MB-231-FOXO3a(A3):ER, MDA-MB-231 and BT474 cells described above were used for ChIP assays using immunoglobulin G (IgG), anti-FOXO3a and anti-FOXM1 antibodies as indicated. After crosslink reversal, the co-immunoprecipitated DNA was amplified by PCR using primers amplifying the VEGF FHRE2-containing region (À351/À186) and resolved in 2% agarose gel. Representative data from three independent experiments are shown. 
Discussion
Signals mediated through VEGFs and their receptors have been shown to be essential for breast cancer carcinogenesis, cell migration (metastasis) and angiogenesis (Lohela et al., 2009 ). Yet, the molecular mechanisms regulating VEGF expression in cancer cells are only partially understood. A previous cDNA microarray study using a colon carcinoma cell line DLD-1 has suggested that FOXO3a can potentially repress VEGF expression (Delpuech et al., 2007) . Our present analysis of breast cancer patient samples revealed that FOXO3a nuclear localisation is significantly but inversely associated with VEGF expression, suggesting FOXO3a negatively regulates VEGF expression in vivo in breast cancer.
Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as models for FOXO3a activation, the hypothesis that FOXO3a regulates VEGF expression was examined and the underlying mechanisms involved explored in this study. lapatinib treatment resulted in inactivation of the PI3K pathway, nuclear translocation and activation of FOXO3a (Hegde et al., 2007) and ultimately reduction in VEGF expression at protein, mRNA and gene promoter levels. Transient transfection and inducible FOXO3a expression experiments showed that FOXO3a represses, whereas FOXM1 activates VEGF expression through a proximal FHRE site of the VEGF promoter, as mutation of this FHRE abrogated the regulation by FOXO3a and FOXM1. ChIP and oligonucleotide pull-down assays further showed that both FOXO3a and FOXM1 bind performed as described to demonstrate effective and specific FOXO3a knockdown. Statistical analyses were done using Student's t test, and were considered very significant at **Po0.01.
binding to HDAC2 in response to lapatinib is likely to be due to the relocation of FOXO3a to the nucleus, whereas the declined in FOXO3a binding to HDAC2 was probably a result of the disassociation in binding between the two proteins as well as a decline in HDAC2 levels, as revealed by immunoprecipitaion and western blot analyses, respectively. Overexpression of FOXM1 has been implicated with metastasis and angiogenesis in a number of malignancies, including glioma, gastric and pancreatic cancer. Consistent with our findings, a recent study has also showed that FOXM1 transcriptionally regulates VEGF expression in glioma cells (Zhang et al., 2008) . It is notable that the FOXM1 responsive sites identified previously locate over 500 bp 5 0 -upstream of the FOXO/ FOXM1-binding site defined in this study and neither of these sites appears to be a consensus FOXO-binding element. Importantly, deletion of site 2 in the present VEGF promoter abolishes responsiveness to FOXO3a, FOXM1 and HDAC, suggesting this FHRE is targeted by FOXO3a and FOXM1. In this study we further showed that FOXM1 functions downstream of FOXO3a, and its activity and expression are negatively regulated by FOXO3a. Nevertheless, FOXM1 is not the sole effector of FOXO3a function. FOXO3a can also negatively regulate gene expression through FOXM1 independent mechanisms, such as by means of HDAC recruitment. The ability of FOXO proteins to repress VEGF expression has been documented in Foxo1-null cells in which VEGF is overexpressed and angiogenesis is deregulated (Furuyama et al., 2004; Park et al., 2009 ). This notion is now supported further by our finding that expression of nuclear FOXO3a expression significantly inversely correlates with VEGF expression in breast cancer patient samples. Consistently, constitutively active FOXO mutants have been shown to inhibit human umbilical vein endothelial cell migration, and capillary tube formation (Lee et al., 2008; Davis et al., 2009) .
In summary, together the present results suggest that FOXO3a can potentially repress VEGF expression, through at least two mechanisms. First, activated FOXO3a can compete off the transcription activator FOXM1 from binding to the FHRE of the VEGF gene promoter. Second, FOXO3a can recruit HDACs to the VEGF promoter to induce chromatin condensation and transcription factor exclusion. Furthermore, FOXO3a has also been shown previously to be able to repress FOXM1 expression at transcriptional levels . Consequently, FOXO3a can repress VEGF expression indirectly via regulating FOXM1 expression. The mechanisms by which FOXO3a represses VEGF expression may represent common means whereby FOXO3a negatively regulates target gene expression. Thus, this study also provides novel understanding on the mechanisms by which FOXO transcription factors repress target gene expression. Furthermore, the findings from this study also suggest that therapeutic strategies targeting FOXO3a or FOXM1 can be used as an alternative or in parallel with anti-VEGF-targeted agents as well as conventional chemotherapy in rational and effective treatment of tumours (Fernandez de Mattos et al., 2008; Gomes et al., 2008; Srivastava et al., 2010) .
Materials and methods
Cell culture
The human breast carcinoma cell lines BT474, SKBR3, MCF-7 and MDA-MB-231 originated from the American Type Culture Collection and were acquired from the Cell Culture Service, Cancer Research UK (London, UK), where they were tested and authenticated. Cell lines used in this study were in culture for o6 months. All cells used were maintained in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum, 2 mM glutamine and 100 units/ml penicillin/streptomycin at 37 1C. Lapatinib was obtained from GlaxoSmithKline (Uxbridge, UK), dissolved in dimethyl sulfoxide and used at a final concentration of 0.1 mM.
Plasmids
For the generation of human VEGF promoter constructs, a 1741-bp VEGF promoter construct was generated using PCR primers 5 0 -ATCTCGAGGAGGCTATGCCAGCTGTAGG-3 0 and 5 0 -GCAAGCTTTCTGCTGGTTTCCAAAATCC-3 0 from the genomic DNA and cloned into the pGL3 basic vector (Promega, Southampton, UK). Putative Forkhead site mutagenesis was performed using the Stratagene (Santa Clara, CA, USA) QuikChange site-directed mutagenesis kit. The HDAC2
WT and HDAC2 C262A/C274A expression plasmids were kind gifts from Dr Antonella Riccio (University College London, UK; Nott et al., 2008) and the FOXO3a(A3) or FOXM1(DN) expression vectors have been described previously (Essafi et al., 2005; Krol et al., 2007; Kwok et al., 2008) .
Luciferase reporter assay, antibodies, Real-time-qPCR and gene silencing with siRNAs See Supplementary Materials and Methods.
Western blotting
Western blotting was performed on whole-cell extracts as described previously (Krol et al., 2007) .
Preparation of nuclear and cytoplasmic extracts Nuclear and cytoplasmic extracts were prepared as described previously (Essafi et al., 2009 ).
Pull-down assays using biotin-labelled oligonucleotides Pull-down assays were performed as described previously (Labied et al., 2006) using the 100 nmol of biotin-labelled double-stranded oligonucleotides: Wild-type (5 0 -GTTTTATC CCTCTTCTTTTTTCTTAAACATTTTTTAAA-3 0 ); Mutant: (5 0 -GTTTTATCCCTGTTCTTTTTTCTTGGGCATTTTTTA AA-3 0 ). The pulled down complexes were then analysed by western blotting.
Tissue microarray and immnohistochemistry
See Figure 1 legend.
ChIP assay
ChIP assay was performed as described (Essafi et al., 2005) using FOXO3a(A3):ER MDA-MB-231 cells treated with or without 200 nM 4-OHT for 24 h before harvesting. DNA fragments were purified using the QIAquick Spin Kit (Qiagen, Crawley, UK).
For PCR, one-twenty-fifth of the extracted DNA was used and amplified in 25 PCR cycles using specific primers. PCRs were then performed on the purified DNA using the following primers: (À351)-5 0 -TCCGGGTTTTATCCCTCTTC-3 0 ; 5 0 -TC TGCTGGTTTCCAAAATCC-3 0 (À186).
Statistical analysis
To test for the relationship between VEGF, FOXM1 and nuclear/ cytoplasmic FOXO3a, statistical analysis was performed using Pearson's correlation test and was considered significant at Pp0.05 and very significant at p0.01. All statistical analysis was performed with SPSS v.16 (SPSS Inc., Chicago, IL, USA).
